IGM-2644

N/A

Report date: 2026/03/19 17:18:42

Base Information

Drug NameIGM-2644

Drug Alias NameIGM-2644

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionLymphocyte differentiation antigen CD38 inhibitorsT cell surface glycoprotein CD3 stimulants

TargetsLymphocyte differentiation antigen CD38T cell surface glycoprotein CD3

Therapy Area/IndicationsAutoimmune DiseasesMultiple Myeloma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesIgm Biosciences Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesIgm Biosciences Inc

Active IndicationsN/A

Inactive IndicationsAutoimmune DiseasesMultiple Myeloma

Other Information

ATC CodeN/A